7:@0.890196:0.957873:0.898787:0.957873:0.898787:0.938882:0.890196:0.938882:0.008591
1:@0.941813:0.186378:0.963291:0.186378:0.963291:0.138900:0.941813:0.138900:0.021478
introduction:@0.794874:0.064721:0.882352:0.064721:0.882352:0.047603:0.794874:0.047603:0.003511:0.008759:0.006387:0.008311:0.008442:0.008423:0.008367:0.008178:0.006387:0.003511:0.008442:0.008759
factors resulting from non-cancer related somatic mutations in different tissues:@0.147059:0.121273:0.850923:0.121273:0.850923:0.100900:0.147059:0.100900:0.006209:0.009291:0.009108:0.006209:0.010843:0.007624:0.007670:0.008834:0.007442:0.009039:0.007510:0.011550:0.004908:0.006437:0.005615:0.011459:0.009861:0.008834:0.006412:0.007442:0.010843:0.017645:0.008834:0.011596:0.010843:0.011756:0.007533:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.008834:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.008834:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.008834:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.008834:0.005615:0.011756:0.008834:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.008834:0.006437:0.005615:0.007533:0.007512:0.011345:0.009039:0.007670
70,71:@0.850908:0.113657:0.877857:0.113657:0.877857:0.101780:0.850908:0.101780:0.006082:0.006082:0.002622:0.006082:0.006082
, :@0.877856:0.121273:0.886461:0.121273:0.886461:0.100900:0.877856:0.100900:0.004497:0.004109
leading  to  suboptimal  consistency  and  precision.  With  further  evidence  of  clinical :@0.147059:0.141852:0.886462:0.141852:0.886462:0.121479:0.147059:0.121479:0.005182:0.009291:0.009291:0.011391:0.005615:0.011459:0.009861:0.004109:0.004965:0.006209:0.011048:0.004109:0.004965:0.007510:0.011345:0.011254:0.010820:0.011048:0.006437:0.005615:0.017577:0.009402:0.005250:0.004109:0.004965:0.008994:0.010843:0.011619:0.007604:0.005615:0.007510:0.006209:0.009039:0.011596:0.009382:0.009724:0.004109:0.004965:0.009085:0.011596:0.011391:0.004109:0.004965:0.011071:0.007442:0.009108:0.008994:0.005615:0.007601:0.005547:0.010843:0.011756:0.004497:0.004109:0.004965:0.019951:0.005273:0.006620:0.011459:0.004109:0.004965:0.006366:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.004109:0.004965:0.009336:0.009838:0.005547:0.011322:0.009039:0.011596:0.008994:0.009039:0.004109:0.004965:0.010843:0.006209:0.004109:0.004965:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004109
utility and multiparametric assays to overcome precision limitations, liquid biopsies will :@0.147059:0.162431:0.886484:0.162431:0.886484:0.142058:0.147059:0.142058:0.011071:0.006437:0.005752:0.005250:0.005273:0.006437:0.009724:0.004040:0.009085:0.011596:0.011391:0.004040:0.017280:0.011550:0.004908:0.006437:0.005273:0.011368:0.009085:0.007898:0.009085:0.017485:0.009131:0.006437:0.007807:0.005547:0.008994:0.004040:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004040:0.006209:0.011048:0.004040:0.010866:0.009633:0.009039:0.007442:0.008994:0.010843:0.017485:0.009039:0.004040:0.011071:0.007442:0.009108:0.008994:0.005615:0.007601:0.005547:0.010843:0.011756:0.004040:0.005250:0.005615:0.017645:0.005273:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.004040:0.005250:0.005547:0.010706:0.011413:0.005547:0.011391:0.004040:0.010820:0.005547:0.010820:0.011185:0.007601:0.005547:0.009039:0.007670:0.004040:0.014723:0.005750:0.005387:0.005250:0.004109
undoubtedly reach their potential in genomic oncology:@0.147059:0.183009:0.612791:0.183009:0.612791:0.162636:0.147059:0.162636:0.011413:0.011596:0.011322:0.010820:0.011345:0.010797:0.006209:0.009108:0.011528:0.005182:0.009724:0.004109:0.007442:0.009291:0.009291:0.008765:0.011459:0.004109:0.006620:0.011299:0.009039:0.005615:0.007807:0.004109:0.011502:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.004109:0.005615:0.011756:0.004109:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004109:0.010843:0.011596:0.008994:0.010934:0.005182:0.011048:0.010546:0.009724
51,52:@0.612790:0.175393:0.639739:0.175393:0.639739:0.163516:0.612790:0.163516:0.006082:0.006082:0.002622:0.006082:0.006082
. :@0.639738:0.183009:0.648344:0.183009:0.648344:0.162636:0.639738:0.162636:0.004497:0.004109
Ovarian cancer:@0.147059:0.247728:0.308761:0.247728:0.308761:0.219618:0.147059:0.219618:0.012957:0.010836:0.012318:0.013103:0.006217:0.012318:0.013626:0.004648:0.012722:0.012318:0.013626:0.012841:0.011069:0.013103
Ovarian cancer (OC) is a type of cancer that still has poor survival perspectives. Despite :@0.147059:0.289578:0.886459:0.289578:0.886459:0.269205:0.147059:0.269205:0.016892:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.004209:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004212:0.006939:0.016775:0.014678:0.006939:0.004209:0.005615:0.007670:0.004212:0.009291:0.004209:0.006437:0.009724:0.011505:0.009039:0.004209:0.010843:0.006209:0.004209:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004212:0.006617:0.011393:0.008811:0.006437:0.004209:0.007510:0.006437:0.005752:0.005387:0.005250:0.004209:0.011391:0.009291:0.007670:0.004209:0.011505:0.011276:0.010843:0.007807:0.004212:0.007510:0.011413:0.008398:0.009838:0.005547:0.009838:0.009405:0.005250:0.004212:0.011502:0.009039:0.007624:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.007670:0.004497:0.004209:0.016230:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.004109
increased knowledge in OC etiology and molecular characteristics, patient survival rates :@0.147059:0.310156:0.886482:0.310156:0.886482:0.289783:0.147059:0.289783:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007875:0.009108:0.011391:0.003652:0.010703:0.011598:0.010866:0.014789:0.005182:0.009108:0.011391:0.009656:0.009039:0.003652:0.005615:0.011756:0.003652:0.016778:0.014678:0.003652:0.009131:0.006437:0.005547:0.010934:0.005182:0.011048:0.010546:0.009724:0.003652:0.009085:0.011598:0.011391:0.003652:0.017485:0.010934:0.005182:0.009108:0.009106:0.011550:0.005433:0.009085:0.007807:0.003652:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.007510:0.006437:0.005545:0.008994:0.007670:0.004497:0.003652:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.003652:0.007512:0.011413:0.008398:0.009838:0.005547:0.009838:0.009405:0.005250:0.003652:0.007898:0.008811:0.006209:0.009039:0.007670:0.004109
have not improved in the last decades worldwide:@0.147059:0.330735:0.553629:0.330735:0.553629:0.310362:0.147059:0.310362:0.011391:0.008925:0.009633:0.009039:0.003766:0.011596:0.010820:0.006437:0.003766:0.005615:0.017280:0.011071:0.007442:0.010866:0.009633:0.009108:0.011391:0.003766:0.005615:0.011756:0.003766:0.006620:0.011299:0.009039:0.003766:0.005433:0.009291:0.007510:0.006437:0.003766:0.011322:0.009108:0.009108:0.009291:0.011322:0.009039:0.007670:0.003766:0.014518:0.010845:0.007601:0.005182:0.011322:0.014723:0.005547:0.011322:0.009039
72,73:@0.553632:0.323119:0.580581:0.323119:0.580581:0.311242:0.553632:0.311242:0.006082:0.006082:0.002622:0.006082:0.006082
. OC is a very heterogeneous disease :@0.580580:0.330735:0.886457:0.330735:0.886457:0.310362:0.580580:0.310362:0.004497:0.003766:0.016778:0.014678:0.003766:0.005615:0.007670:0.003766:0.009291:0.003766:0.009633:0.009039:0.008400:0.009724:0.003766:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011598:0.009106:0.010820:0.011413:0.007670:0.003766:0.011391:0.005615:0.007873:0.009291:0.009291:0.007875:0.009039:0.004109
with many subtypes. These subtypes differ in their cell of origin, molecular characteristics :@0.147059:0.351314:0.886567:0.351314:0.886567:0.330941:0.147059:0.330941:0.014723:0.005273:0.006620:0.011459:0.003104:0.017577:0.009085:0.011368:0.009724:0.003104:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.004497:0.003104:0.011470:0.011311:0.009039:0.007873:0.009039:0.003104:0.007512:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.003104:0.011391:0.005615:0.005969:0.005787:0.009039:0.007807:0.003104:0.005615:0.011756:0.003104:0.006620:0.011299:0.009039:0.005615:0.007807:0.003104:0.008994:0.008948:0.005385:0.005250:0.003104:0.010845:0.006209:0.003093:0.010843:0.007807:0.005615:0.009861:0.005615:0.011756:0.004497:0.003104:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005433:0.009085:0.007807:0.003104:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.007510:0.006437:0.005547:0.008994:0.007670:0.004109
and disease prognosis:@0.147059:0.371892:0.331682:0.371892:0.331682:0.351520:0.147059:0.351520:0.009085:0.011596:0.011391:0.004657:0.011391:0.005615:0.007875:0.009291:0.009291:0.007875:0.009039:0.004657:0.011071:0.007442:0.011048:0.009861:0.011596:0.010957:0.007601:0.005615:0.007670
72,74:@0.331699:0.364276:0.358648:0.364276:0.358648:0.352399:0.331699:0.352399:0.006082:0.006082:0.002622:0.006082:0.006082
. Epithelial OC is more common and originates from different :@0.358647:0.371892:0.886379:0.371892:0.886379:0.351520:0.358647:0.351520:0.004497:0.004657:0.011505:0.011071:0.005273:0.006620:0.011299:0.008948:0.005250:0.005798:0.009405:0.005250:0.004657:0.016778:0.014678:0.004657:0.005615:0.007670:0.004657:0.017485:0.010843:0.007442:0.009039:0.004657:0.008994:0.010843:0.017645:0.017485:0.010843:0.011756:0.004657:0.009085:0.011596:0.011391:0.004657:0.010843:0.007807:0.005615:0.009861:0.005615:0.011687:0.008811:0.006209:0.009039:0.007670:0.004657:0.006414:0.007442:0.010843:0.017645:0.004657:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.004109
cell types surrounding the ovary, mainly from the fallopian tube, while the rarer non-:@0.147059:0.392471:0.882376:0.392471:0.882376:0.372098:0.147059:0.372098:0.008994:0.008948:0.005387:0.005250:0.005935:0.006437:0.009724:0.011505:0.009039:0.007670:0.005935:0.007510:0.011413:0.007807:0.007442:0.010820:0.011413:0.011596:0.011391:0.005615:0.011459:0.009861:0.005935:0.006620:0.011299:0.009039:0.005935:0.010866:0.009838:0.009085:0.008398:0.007989:0.004497:0.005935:0.017577:0.009085:0.005615:0.011870:0.005182:0.009724:0.005935:0.006414:0.007442:0.010843:0.017645:0.005935:0.006620:0.011299:0.009039:0.005935:0.006209:0.009405:0.005387:0.005182:0.010820:0.011071:0.005798:0.009085:0.011756:0.005935:0.006163:0.011345:0.011254:0.008743:0.004497:0.005935:0.014792:0.011459:0.005752:0.005182:0.009039:0.005935:0.006620:0.011299:0.009039:0.005935:0.007898:0.009085:0.007442:0.009039:0.007807:0.005935:0.011596:0.010843:0.011756:0.007533
epithelial OC subtypes arise from within the ovary:@0.147059:0.413050:0.574308:0.413050:0.574308:0.392677:0.147059:0.392677:0.009131:0.011071:0.005273:0.006620:0.011299:0.008948:0.005250:0.005798:0.009405:0.005250:0.004520:0.016778:0.014678:0.004520:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.004520:0.009085:0.007807:0.005615:0.007875:0.009039:0.004520:0.006414:0.007442:0.010843:0.017645:0.004520:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004520:0.006617:0.011302:0.009039:0.004520:0.010866:0.009838:0.009087:0.008398:0.009724
74,75:@0.574254:0.405434:0.601203:0.405434:0.601203:0.393556:0.574254:0.393556:0.006082:0.006082:0.002622:0.006082:0.006082
. The main histopathological type :@0.601202:0.413050:0.886494:0.413050:0.886494:0.392677:0.601202:0.392677:0.004497:0.004520:0.011470:0.011311:0.009039:0.004520:0.017577:0.009085:0.005615:0.011756:0.004520:0.011459:0.005615:0.007512:0.006207:0.010822:0.011365:0.008811:0.006620:0.011302:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.004520:0.006437:0.009724:0.011505:0.009039:0.004109
of epithelial OC is high grade serous carcinomas (HGSCs), which accounts for 70% of OC :@0.147059:0.433629:0.886393:0.433629:0.886393:0.413256:0.147059:0.413256:0.010843:0.006209:0.002785:0.009131:0.011071:0.005273:0.006620:0.011299:0.008948:0.005250:0.005798:0.009405:0.005250:0.002785:0.016778:0.014678:0.002785:0.005615:0.007670:0.002785:0.011459:0.005615:0.009930:0.011459:0.002785:0.009861:0.007898:0.009291:0.011322:0.009039:0.002785:0.007875:0.009039:0.007442:0.010820:0.011413:0.007670:0.002785:0.009108:0.009085:0.007442:0.008994:0.005615:0.011596:0.010843:0.017577:0.009291:0.007670:0.002785:0.006939:0.016410:0.015682:0.010112:0.014678:0.007670:0.006939:0.004497:0.002785:0.014792:0.011459:0.005547:0.008765:0.011459:0.002785:0.009291:0.008994:0.008994:0.010820:0.011413:0.011391:0.006437:0.007670:0.002785:0.006024:0.010845:0.007807:0.002785:0.010432:0.010432:0.015043:0.002785:0.010843:0.006209:0.002785:0.016778:0.014678:0.004109
cases and deaths:@0.147059:0.454207:0.286781:0.454207:0.286781:0.433834:0.147059:0.433834:0.009108:0.009291:0.007875:0.009039:0.007670:0.004816:0.009085:0.011596:0.011391:0.004816:0.011322:0.009291:0.008811:0.006620:0.011322:0.007670
73,76:@0.286769:0.446591:0.313718:0.446591:0.313718:0.434714:0.286769:0.434714:0.006082:0.006082:0.002622:0.006082:0.006082
. HGSCs are genomically characterized by somatic TP53 mutations :@0.313717:0.454207:0.886507:0.454207:0.886507:0.433834:0.313717:0.433834:0.004497:0.004816:0.016412:0.015682:0.010112:0.014678:0.007670:0.004816:0.009085:0.007442:0.009039:0.004816:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.009108:0.009405:0.005387:0.005182:0.009724:0.004816:0.008768:0.011391:0.009085:0.007898:0.009291:0.009106:0.006211:0.009039:0.007807:0.005615:0.008834:0.009106:0.011391:0.004816:0.010840:0.009724:0.004816:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004816:0.013354:0.012167:0.010432:0.010432:0.004816:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004109
and large copy number aberrations and aneuploidies. Moreover, half of the HGSCs :@0.147059:0.474786:0.886464:0.474786:0.886464:0.454413:0.147059:0.454413:0.009085:0.011596:0.011391:0.007830:0.005433:0.009085:0.007624:0.009656:0.009039:0.007830:0.008994:0.010820:0.011094:0.009724:0.007830:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.007830:0.009108:0.011254:0.009039:0.007807:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.007830:0.009085:0.011596:0.011391:0.007830:0.009085:0.011596:0.009131:0.011071:0.011162:0.005182:0.010843:0.005547:0.011391:0.005547:0.009039:0.007670:0.004497:0.007830:0.018969:0.010843:0.007442:0.009108:0.010866:0.009633:0.009039:0.006255:0.004497:0.007830:0.011391:0.009405:0.005250:0.006209:0.007830:0.010843:0.006209:0.007830:0.006620:0.011299:0.009039:0.007830:0.016412:0.015682:0.010112:0.014678:0.007670:0.004109
show homologous recombination deficiency, mainly due to mutations in BRCA1 and :@0.147059:0.495365:0.886418:0.495365:0.886418:0.474992:0.147059:0.474992:0.007556:0.011299:0.010866:0.014723:0.006163:0.011299:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.006163:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.006163:0.011322:0.009039:0.005684:0.005615:0.008994:0.005547:0.009039:0.011596:0.009382:0.007989:0.004497:0.006163:0.017577:0.009085:0.005615:0.011870:0.005182:0.009724:0.006163:0.011048:0.011345:0.009039:0.006163:0.006209:0.011048:0.006163:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006163:0.005615:0.011756:0.006163:0.012463:0.013308:0.014678:0.014929:0.010432:0.006163:0.009085:0.011596:0.011391:0.004109
BRCA2. However, besides these, few genes are recurrently mutated in these HGSCs:@0.147059:0.515943:0.850877:0.515943:0.850877:0.495570:0.147059:0.495570:0.012463:0.013308:0.014678:0.014929:0.010432:0.004497:0.004588:0.016207:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.004588:0.011254:0.009039:0.007601:0.005547:0.011322:0.009039:0.007670:0.004588:0.006620:0.011302:0.009039:0.007873:0.008743:0.004497:0.004588:0.006026:0.009336:0.014723:0.004588:0.009656:0.009039:0.011596:0.009039:0.007670:0.004588:0.009085:0.007442:0.009039:0.004588:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006620:0.005182:0.009724:0.004588:0.017280:0.011071:0.006551:0.008811:0.006209:0.009108:0.011391:0.004588:0.005615:0.011756:0.004588:0.006620:0.011299:0.009039:0.007875:0.009039:0.004588:0.016412:0.015682:0.010112:0.014678:0.007670
77,78:@0.850908:0.508327:0.877857:0.508327:0.877857:0.496450:0.850908:0.496450:0.006082:0.006082:0.002622:0.006082:0.006082
. :@0.877856:0.515943:0.886462:0.515943:0.886462:0.495570:0.877856:0.495570:0.004497:0.004109
Furthermore, one fifth of the OC cases are partially explained by germline variants in :@0.147059:0.536522:0.886555:0.536522:0.886555:0.516149:0.147059:0.516149:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.005912:0.010843:0.011596:0.009039:0.005912:0.005684:0.005684:0.006197:0.006380:0.011459:0.005912:0.010843:0.006209:0.005912:0.006620:0.011299:0.009039:0.005912:0.016778:0.014678:0.005912:0.009108:0.009291:0.007875:0.009039:0.007670:0.005912:0.009085:0.007442:0.009039:0.005912:0.011368:0.009085:0.007967:0.006437:0.005798:0.009402:0.005387:0.005182:0.009724:0.005912:0.009108:0.010089:0.011162:0.005433:0.009085:0.005615:0.011596:0.009108:0.011391:0.005912:0.010843:0.009724:0.005912:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.005912:0.009838:0.009087:0.007807:0.005796:0.009085:0.011393:0.006437:0.007670:0.005912:0.005615:0.011756:0.004109
genes involved in DNA repair like BRCA1, BRCA2, RAD51, PALB1 or CHEK2:@0.147059:0.557101:0.846563:0.557101:0.846563:0.536728:0.147059:0.536728:0.009656:0.009039:0.011596:0.009039:0.007670:0.007053:0.005615:0.011368:0.009633:0.010934:0.005182:0.009633:0.009108:0.011391:0.007053:0.005615:0.011756:0.007053:0.015773:0.015408:0.014929:0.007053:0.007442:0.009131:0.011368:0.009085:0.005615:0.007807:0.007053:0.005250:0.005752:0.010272:0.009039:0.007053:0.012463:0.013308:0.014678:0.014929:0.010432:0.004497:0.007053:0.012463:0.013308:0.014678:0.014929:0.010432:0.004497:0.007053:0.013650:0.014929:0.016139:0.010432:0.010432:0.004497:0.007053:0.010249:0.014929:0.011619:0.012646:0.010432:0.007053:0.010843:0.007807:0.007053:0.014678:0.016846:0.012098:0.014541:0.010432
79–81:@0.846649:0.549485:0.877857:0.549485:0.877857:0.537607:0.846649:0.537607:0.006082:0.006082:0.006880:0.006082:0.006082
. :@0.877856:0.557101:0.886461:0.557101:0.886461:0.536728:0.877856:0.536728:0.004497:0.004109
Other subtypes of epithelial OC are low grade serous carcinomas (LGSC), endometrioid :@0.147059:0.577679:0.886530:0.577679:0.886530:0.557307:0.147059:0.557307:0.016504:0.006620:0.011299:0.009039:0.007807:0.003721:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.003721:0.010845:0.006209:0.003721:0.009128:0.011073:0.005271:0.006620:0.011299:0.008950:0.005250:0.005796:0.009405:0.005250:0.003721:0.016778:0.014678:0.003721:0.009085:0.007442:0.009039:0.003721:0.005182:0.010866:0.014723:0.003721:0.009861:0.007898:0.009291:0.011322:0.009039:0.003721:0.007873:0.009039:0.007442:0.010820:0.011413:0.007670:0.003721:0.009106:0.009087:0.007442:0.008994:0.005615:0.011596:0.010843:0.017577:0.009291:0.007670:0.003721:0.006939:0.011528:0.015682:0.010112:0.014678:0.006939:0.004497:0.003721:0.009039:0.011596:0.011322:0.010843:0.017485:0.009131:0.006437:0.007807:0.005547:0.010843:0.005547:0.011391:0.004109
carcinomas (END), clear cell carcinomas (CCC) and mucinous carcinomas (MC). These :@0.147059:0.598258:0.886503:0.598258:0.886503:0.577885:0.147059:0.577885:0.009108:0.009085:0.007442:0.008994:0.005615:0.011596:0.010843:0.017577:0.009291:0.007670:0.003629:0.006939:0.012098:0.016230:0.016139:0.006939:0.004497:0.003629:0.008768:0.005182:0.009288:0.009085:0.007807:0.003629:0.008994:0.008948:0.005385:0.005250:0.003629:0.009108:0.009085:0.007442:0.008994:0.005615:0.011596:0.010843:0.017577:0.009291:0.007670:0.003629:0.006939:0.014744:0.014746:0.014678:0.006939:0.003629:0.009085:0.011596:0.011391:0.003629:0.017280:0.011345:0.008994:0.005615:0.011596:0.010820:0.011413:0.007670:0.003629:0.009108:0.009085:0.007442:0.008994:0.005615:0.011596:0.010843:0.017577:0.009291:0.007670:0.003629:0.006939:0.019197:0.014678:0.006939:0.004497:0.003629:0.011470:0.011311:0.009039:0.007873:0.009039:0.004109
subtypes harbor somatic mutations in different genes, such ARID1A, PTEN, PIK3CA, :@0.147059:0.618837:0.886464:0.618837:0.886464:0.598464:0.147059:0.598464:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.005330:0.011391:0.009085:0.007715:0.011254:0.010843:0.007807:0.005330:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.005330:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.005330:0.005615:0.011756:0.005330:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005330:0.009656:0.009039:0.011596:0.009039:0.007670:0.004497:0.005330:0.007510:0.011345:0.008765:0.011459:0.005330:0.014929:0.013376:0.007259:0.016139:0.010432:0.014929:0.004497:0.005330:0.012167:0.013354:0.012098:0.016230:0.004497:0.005330:0.011664:0.007259:0.014541:0.010432:0.014678:0.014929:0.004497:0.004109
CTNNB1 and KRAS .:@0.147059:0.639416:0.340944:0.639416:0.340944:0.619043:0.147059:0.619043:0.014678:0.013354:0.016230:0.016230:0.012646:0.010432:0.004109:0.009083:0.011598:0.011391:0.004109:0.014541:0.013648:0.015066:0.010112:0.012164:0.004497
82:@0.324284:0.631800:0.336448:0.631800:0.336448:0.619922:0.324284:0.619922:0.006082:0.006082
The main treatment for patients with OC consists of debulking surgery and chemotherapy, :@0.147059:0.680573:0.886544:0.680573:0.886544:0.660200:0.147059:0.660200:0.011470:0.011311:0.009039:0.002237:0.017577:0.009085:0.005615:0.011756:0.002237:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.002226:0.006026:0.010843:0.007807:0.002237:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.002237:0.014723:0.005273:0.006620:0.011459:0.002226:0.016778:0.014678:0.002237:0.008994:0.010843:0.011619:0.007601:0.005615:0.007510:0.006437:0.007670:0.002237:0.010843:0.006209:0.002237:0.011322:0.008902:0.010797:0.011550:0.005385:0.010708:0.005615:0.011459:0.009861:0.002226:0.007510:0.011413:0.007624:0.009656:0.009039:0.008400:0.009724:0.002237:0.009085:0.011596:0.011391:0.002237:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.007989:0.004497:0.004109
mainly with a combination of carboplatin and paclitaxel. However, OC often recurs with :@0.147059:0.701152:0.886343:0.701152:0.886343:0.680779:0.147059:0.680779:0.017577:0.009085:0.005615:0.011870:0.005182:0.009724:0.003629:0.014723:0.005273:0.006620:0.011459:0.003629:0.009291:0.003629:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.003629:0.010843:0.006209:0.003629:0.009108:0.009085:0.007715:0.011251:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.003629:0.009085:0.011596:0.011391:0.003629:0.011368:0.009291:0.008765:0.005250:0.005271:0.006551:0.009291:0.009884:0.008948:0.004976:0.004497:0.003629:0.016205:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.003629:0.016778:0.014678:0.003629:0.010843:0.006197:0.005971:0.009039:0.011756:0.003629:0.007442:0.009108:0.009108:0.011413:0.007624:0.007670:0.003629:0.014723:0.005271:0.006620:0.011459:0.004109
an acquired chemotherapy resistance, so there is a need for targeted treatments with less :@0.147059:0.721730:0.886348:0.721730:0.886348:0.701357:0.147059:0.701357:0.009085:0.011756:0.004177:0.009291:0.008994:0.010706:0.011413:0.005615:0.007442:0.009106:0.011391:0.004177:0.008765:0.011302:0.009039:0.017485:0.010820:0.006617:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.004177:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011596:0.008994:0.008743:0.004497:0.004177:0.007875:0.011048:0.004177:0.006617:0.011302:0.009039:0.007442:0.009039:0.004177:0.005615:0.007670:0.004177:0.009291:0.004177:0.011596:0.009108:0.009108:0.011391:0.004177:0.006024:0.010845:0.007807:0.004177:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004177:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.007670:0.004177:0.014723:0.005273:0.006620:0.011459:0.004177:0.005182:0.009039:0.007533:0.007670:0.004109
harmful side effects. For example several PARP-inhibitors have been recently approved :@0.147059:0.742309:0.886487:0.742309:0.886487:0.721936:0.147059:0.721936:0.011391:0.009085:0.007807:0.017645:0.006369:0.011550:0.005250:0.004976:0.007601:0.005547:0.011322:0.009039:0.004976:0.009039:0.005969:0.005787:0.009108:0.009108:0.006437:0.007670:0.004497:0.004976:0.010683:0.010843:0.007807:0.004976:0.009108:0.010089:0.009085:0.017280:0.011162:0.005182:0.009039:0.004976:0.007875:0.009336:0.009633:0.009039:0.007898:0.009405:0.005250:0.004976:0.010249:0.014929:0.013376:0.010592:0.007533:0.005615:0.011868:0.011459:0.005547:0.010820:0.005273:0.006209:0.010843:0.007624:0.007670:0.004976:0.011391:0.008925:0.009635:0.009039:0.004976:0.011251:0.009108:0.009039:0.011756:0.004976:0.007442:0.009108:0.008994:0.009039:0.011391:0.006620:0.005182:0.009724:0.004976:0.008813:0.011048:0.011071:0.007442:0.010863:0.009635:0.009108:0.011391:0.004109
for  patients  with OC  with  homologous  recombination  (HR)  deficiencies  due  to :@0.147059:0.762888:0.886471:0.762888:0.886471:0.742515:0.147059:0.742515:0.006026:0.010843:0.007807:0.004109:0.007270:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004109:0.007270:0.014723:0.005273:0.006617:0.011459:0.011391:0.016775:0.014678:0.004109:0.007270:0.014723:0.005273:0.006620:0.011459:0.004109:0.007270:0.011299:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.004109:0.007270:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109:0.007270:0.006939:0.016846:0.013376:0.006939:0.004109:0.007270:0.011322:0.009039:0.005684:0.005615:0.008994:0.005547:0.009039:0.011596:0.008994:0.005547:0.009039:0.007670:0.004109:0.007270:0.011048:0.011345:0.009039:0.004109:0.007270:0.006209:0.011048:0.004109
mutations in BRCA1, BRCA2 or other genes in the HR pathway:@0.147059:0.783466:0.687914:0.783466:0.687914:0.763094:0.147059:0.763094:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004451:0.005615:0.011756:0.004451:0.012463:0.013308:0.014678:0.014929:0.010432:0.004497:0.004451:0.012463:0.013308:0.014678:0.014929:0.010432:0.004451:0.010843:0.007807:0.004451:0.010820:0.006620:0.011299:0.009039:0.007807:0.004451:0.009656:0.009039:0.011596:0.009039:0.007670:0.004451:0.005615:0.011756:0.004451:0.006620:0.011299:0.009039:0.004451:0.016846:0.013376:0.004451:0.011368:0.008811:0.006620:0.011069:0.014723:0.008925:0.009724
83–85:@0.687913:0.775850:0.719120:0.775850:0.719120:0.763973:0.687913:0.763973:0.006082:0.006082:0.006880:0.006082:0.006082
. Furthermore, OC, :@0.719119:0.783466:0.886462:0.783466:0.886462:0.763094:0.719119:0.763094:0.004497:0.004451:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004451:0.016778:0.014678:0.004497:0.004109
especially HGSCs, presents with high inter- and intra-patient genomic heterogeneity:@0.147059:0.804045:0.850850:0.804045:0.850850:0.783672:0.147059:0.783672:0.009039:0.007510:0.011505:0.009108:0.008994:0.005798:0.009402:0.005387:0.005182:0.009724:0.003561:0.016412:0.015682:0.010112:0.014678:0.007670:0.004497:0.003561:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.007670:0.003561:0.014723:0.005271:0.006620:0.011459:0.003561:0.011459:0.005615:0.009930:0.011459:0.003561:0.005615:0.011391:0.006209:0.009039:0.007236:0.007533:0.003561:0.009087:0.011596:0.011391:0.003561:0.005615:0.011388:0.006437:0.007898:0.009291:0.007533:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.003561:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.003561:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724
78,86:@0.850908:0.796429:0.877857:0.796429:0.877857:0.784552:0.850908:0.784552:0.006082:0.006082:0.002622:0.006082:0.006082
, :@0.877856:0.804045:0.886461:0.804045:0.886461:0.783672:0.877856:0.783672:0.004497:0.004109
highlighting the need of patient-specific treatment approaches to improve prognosis in :@0.147059:0.824624:0.886462:0.824624:0.886462:0.804251:0.147059:0.804251:0.011459:0.005615:0.009930:0.011573:0.005250:0.005615:0.009927:0.011094:0.006437:0.005615:0.011459:0.009861:0.004988:0.006620:0.011299:0.009039:0.004988:0.011598:0.009106:0.009108:0.011391:0.004988:0.010843:0.006209:0.004988:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004988:0.006437:0.007442:0.009288:0.008811:0.006437:0.017488:0.009039:0.011391:0.006437:0.004988:0.008811:0.011048:0.011071:0.007442:0.011137:0.009291:0.008768:0.011299:0.009039:0.007670:0.004988:0.006209:0.011048:0.004988:0.005615:0.017280:0.011071:0.007442:0.010866:0.009633:0.009039:0.004988:0.011071:0.007442:0.011048:0.009861:0.011596:0.010957:0.007601:0.005615:0.007670:0.004988:0.005615:0.011756:0.004109
patients with OC.:@0.147059:0.845203:0.296001:0.845203:0.296001:0.824830:0.147059:0.824830:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004109:0.014723:0.005271:0.006620:0.011459:0.004109:0.016778:0.014678:0.004497
There is however limited success in oncology when translating therapeutics and drug :@0.147059:0.886360:0.886439:0.886360:0.886439:0.865987:0.147059:0.865987:0.011470:0.011311:0.009039:0.007442:0.009039:0.006323:0.005615:0.007670:0.006323:0.011299:0.010866:0.014518:0.009336:0.009633:0.009039:0.007807:0.006323:0.005250:0.005615:0.017645:0.005271:0.006209:0.009108:0.011391:0.006323:0.007510:0.011345:0.008994:0.008994:0.009039:0.007533:0.007670:0.006323:0.005615:0.011756:0.006323:0.010843:0.011596:0.008994:0.010934:0.005182:0.011048:0.010546:0.009724:0.006323:0.014792:0.011299:0.009039:0.011756:0.006323:0.006437:0.007896:0.009087:0.011619:0.007556:0.005433:0.008811:0.006437:0.005615:0.011459:0.009861:0.006323:0.006620:0.011302:0.009039:0.007896:0.008811:0.011505:0.009131:0.011071:0.006437:0.005547:0.008994:0.007670:0.006323:0.009085:0.011596:0.011391:0.006323:0.011391:0.007967:0.011413:0.009861:0.004109
development from scientific research to the clinic . Robust model systems of OC, :@0.147059:0.906939:0.886482:0.906939:0.886482:0.886566:0.147059:0.886566:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011071:0.017485:0.009039:0.011391:0.006437:0.008765:0.006412:0.007442:0.010843:0.017645:0.008765:0.007875:0.008994:0.005547:0.009039:0.011391:0.006437:0.005615:0.005684:0.005613:0.008994:0.008765:0.007442:0.009039:0.007875:0.009288:0.009087:0.007442:0.008765:0.011459:0.008765:0.006209:0.011048:0.008765:0.006620:0.011302:0.009039:0.008765:0.008765:0.005250:0.005615:0.011756:0.005547:0.008994:0.012141:0.004497:0.008765:0.013696:0.010957:0.010797:0.011413:0.007510:0.006437:0.008765:0.017485:0.011276:0.011322:0.008948:0.005250:0.008765:0.007761:0.009724:0.007510:0.006209:0.009039:0.017508:0.007670:0.008765:0.010843:0.006209:0.008765:0.016778:0.014678:0.004497:0.004109
87:@0.588367:0.899323:0.600531:0.899323:0.600531:0.887445:0.588367:0.887445:0.006082:0.006082